Book contents
- Bipolar II Disorder
- Bipolar II Disorder
- Copyright page
- Dedication
- Contents
- Contributors
- Preface to the Third Edition
- Acknowledgements
- Section 1 Domain Chapters
- Section 2 Management Commentaries
- 18 Introduction to Management Commentaries
- 19 Management Commentary
- 20 Management Commentary
- 21 Management Commentary
- 22 Management Commentary
- 23 Management Commentary
- 24 Management Commentary
- 25 Management Commentary
- 26 Management Commentary
- 27 Management Commentary
- 28 Management Commentary
- 29 Management Commentary
- 30 Management Commentary
- 31 Management Commentary
- 32 Management Commentary
- 33 Management commentary
- 34 Management Commentary
- 35 Management Commentary
- 36 Management Commentary
- Section 3 Conclusion
- Index
- References
19 - Management Commentary
from Section 2 - Management Commentaries
Published online by Cambridge University Press: 17 December 2018
Edited by
Book contents
- Bipolar II Disorder
- Bipolar II Disorder
- Copyright page
- Dedication
- Contents
- Contributors
- Preface to the Third Edition
- Acknowledgements
- Section 1 Domain Chapters
- Section 2 Management Commentaries
- 18 Introduction to Management Commentaries
- 19 Management Commentary
- 20 Management Commentary
- 21 Management Commentary
- 22 Management Commentary
- 23 Management Commentary
- 24 Management Commentary
- 25 Management Commentary
- 26 Management Commentary
- 27 Management Commentary
- 28 Management Commentary
- 29 Management Commentary
- 30 Management Commentary
- 31 Management Commentary
- 32 Management Commentary
- 33 Management commentary
- 34 Management Commentary
- 35 Management Commentary
- 36 Management Commentary
- Section 3 Conclusion
- Index
- References
- Type
- Chapter
- Information
- Bipolar II DisorderModelling, Measuring and Managing, pp. 213 - 217Publisher: Cambridge University PressPrint publication year: 2019
References
American Psychiatric Association. (2002). Practice guidelines for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry, 159, 1–50.Google Scholar
Amsterdam, J.D., Garcia-Espana, F., Schweizer, E., et al. (1998). Fluoxetine and bipolar II major depressive episode. Journal of Clinical Psychopharmacology, 18, 435–40.Google Scholar
Amsterdam, J. D., Shults, J., Brunswick, D. J., et al. (2004). Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression – low manic switch rate. Bipolar Disorders, 6, 75–81.CrossRefGoogle ScholarPubMed
Amsterdam, J. D., Wang, C.-H., Schwarz, M., et al. (2009). Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. Journal of Affective Disorders, 112, 219–30.Google Scholar
Amsterdam, J. D., Wang, G., and Shults, J. (2010). Venlafaxine monotherapy of bipolar II major depressive episode in non-responders to prior lithium monotherapy: a cross-over study. Acta Psychiatrica Scandinavia, 121, 201–8.Google Scholar
Amsterdam, J. D., Luo, L., and Shults, J. (2013a). Effectiveness and mood conversion rate of short-term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression. Journal of Clinical Psychopharmacology, 33, 420–4.Google Scholar
Amsterdam, J. D., Luo, L., Shults, J. (2013b). Efficacy and mood conversion rate during long-term fluoxetine versus lithium monotherapy in rapid and non-rapid cycling bipolar type II patients. British Journal of Psychiatry, 202, 301–6.Google Scholar
Amsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., et al. (2015). Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. Journal of Affective Disorders, 185, 31–7.Google Scholar
Amsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., et al. (2016). Effectiveness and mood conversion rate of short-term venlafaxine versus lithium monotherapy of bipolar type II major depressive episode – a randomized, double-blind, prospective study. British Journal of Psychiatry, 208, 359–65.Google Scholar
Amsterdam, J. D., and Shults, J. (2005). Fluoxetine monotherapy for bipolar type II and bipolar NOS major depression – a double-blind, placebo-substitution, continuation study. International Journal of Clinical Psychopharmacology, 20, 357–64.CrossRefGoogle ScholarPubMed
Amsterdam, J. D., and Shults, J. (2008). Comparison of short-term venlafaxine versus lithium monotherapy of bipolar II major depressive episode: a randomized open-label study. Journal of Clinical Psychopharmacology, 28, 171–81.CrossRefGoogle ScholarPubMed
Amsterdam, J. D., and Shults, J. (2010a). Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. Low mood conversion rate during initial fluoxetine monotherapy of bipolar type II major depressive episode. Journal of Clinical Psychopharmacology, 30, 306–11.Google Scholar
Amsterdam, J. D., and Shults, J. (2010b). Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar type II disorder – a randomized, double-blind, placebo-substitution trial. American Journal of Psychiatry, 167, 792–800.CrossRefGoogle Scholar
Fountoulakis, K. N., Vieta, E., Sanchez-Moreno, J., et al. (2005). Treatment guidelines for bipolar disorder: a critical review. Journal of Affective Disorders, 86, 1–10.Google Scholar
Lorenzo-Luaces, L., Amsterdam, J. D., Soeller, I., et al. (2016). Rapid versus non-rapid bipolar II depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatrica Scandinavia, 133, 459–69.Google Scholar
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., et al. (2013). The International Society for Bipolar Disorders (ISBD) Task Force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170, 1249–62.Google Scholar
Parker, G., Tully, L., Olley, A., et al. (2006). SSRIs as mood stabilizers for bipolar II disorder: a proof of concept study. Journal of Affective Disorders, 92, 205–14.CrossRefGoogle ScholarPubMed
Swartz, H. A., Rucci, P., Thase, M. E., et al. (2017). Psychotherapy alone and combined with medication as treatments for bipolar II depression: a randomized controlled trial. Journal of Clinical Psychiatry, doi: 10.4088/JCP.16m11027.Google Scholar
- 1
- Cited by